Simpler Regimens and Less Frequent Doses
"I think there's an interesting paradigm developing in HIV, whether we're going to see the further development and refinement of single-tablet regimens that are once-daily, with great tolerability. The cobicistat-assisted darunavir, the elvitegravir-cobicistat have already been great and the coming of dolutegravir and abacavir/3TC are all very exciting options.
"At the same time, there's an emerging second stream of agents that might be given once a month, or agents that might be given once every two months. So the issue about what will be better for keeping people who are in care, and keeping people engaged -- whether it's less frequent dosing regimens or simple, easy, well-tolerated once daily -- that's something that I'm looking forward to seeing data about."
-- Richard Elion, Director of Clinical Research, Whitman Walker Health.